Zhiwei Zhou

University of Southampton

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Rui‐Hua Xu

Sun Yat-sen University

Yuanfang Li

Sun Yat-sen University Cancer Center

Yingbo Chen

State Key Laboratory of Oncology in South China

Run‐Cong Nie

Sun Yat-sen University

Yu‐Hong Li

Chinese Center For Disease Control and Prevention

Shuqiang Yuan

Sun Yat-sen University

Feng‐Hua Wang

Sun Yat-sen University

Weiguo Su

Hua Medicine (China)

Xiaowei Sun

Sun Yat-sen University Cancer Center

Jianming Xu

Chinese PLA General Hospital

Cooperative Institutions

Sun Yat-sen University

Sun Yat-sen University Cancer Center

State Key Laboratory of Oncology in South China

Chinese Academy of Medical Sciences & Peking Union Medical College

Ministry of Agriculture and Rural Affairs

Chinese Academy of Sciences

Huazhong Agricultural University

Key Laboratory of Guangdong Province

Guangdong Academy of Agricultural Sciences

Shanghai Jiao Tong University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs.

Journal of Clinical Oncology (2022)

Jie Li Jianming Xu Lin Shen Chunmei Bai Zhiwei Zhou

4126 Background: Surufatinib is a small-molecule inhibitor of VEGFR1, 2, & 3, FGFR1, and CSF-1R. Surufatinib demonstrated prolonged PFS and tolerable safety in two phase 3 studies in advanced neuroendocrine tumors (NETs) of pancreatic (SANET-p; NCT02589821) and extrapancreatic (SANET-ep; NCT02588170) origin (Xu, 2020 Lancet Oncology). Detailed outcomes on safety from these 2 studies are reported here as a pooled analysis. Methods: Data is pooled from SANET-p and SANET-ep studies which have similar designs including a 2:1 randomization of surufatinib to placebo in patients ≥18 years with advanced, well differentiated NETs, progressing on or after ≤2 prior therapies. Surufatinib 300 mg or placebo, was administered once daily until disease progression or unacceptable toxicity. Safety outcomes for each pooled treatment group are reported as treatment-emergent adverse events (TEAE) assessed by NCI-CTC 4.03. Patients were included if they had received study treatment during the double-blinded phase of the studies. Results: As of 30 th June 2020, 396 patients were assigned to the surufatinib (n = 263) and placebo (n = 133) groups. Median treatment duration was longer with surufatinib 7.4 months (range 0.1–41.4) compared with placebo 4.6 months (range 0.1–39.9). 29% of patients reached more than 12 months of treatment with surufatinib group compared to 11% with placebo. The mean relative dose intensity was 87.56% in the surufatinib group and 97.01% in the placebo group. Most common TEAEs (surufatinib vs placebo) were proteinuria 68.8% vs 54.9%, hypertension 68.4% vs 27.1%, and diarrhea 49% vs 22.6%. Most common grade ≥3 TEAE were hypertension 38.8% vs 13.5%, proteinuria 14.8% vs 0.8% and hypertriglyceridaemia 5.3% vs 0%. Deaths due to TEAEs were comparable between groups 2.7% vs 2.3%. TEAEs led to dose reductions in 43.0% vs 6.8% of patients and dose interruptions in 47.1% vs 29.3% of patients. The majority of patients (83.3% vs 93.2%) were managed without discontinuation because of TEAE. Median onset of proteinuria and hypertension were < 1 month in both groups. Median (range) onset was 0.95 months (0.16–30.36) vs 0.95 months (0.23–16.95) for proteinuria and 0.49 months (0.03–31.18) vs 0.89 months (0.03–14.75) for hypertension. Among patients with hypertension, 59% (n = 111) vs 28% (n = 11) received antihypertensive medication. Conclusions: Surufatinib was generally well tolerated in this pooled analysis and the safety profile was consistent with its previously reported data. The monitoring and management of hypertension and proteinuria are important for patients receiving surufatinib. Clinical trial information: NCT02589821; NCT02588170. [Table: see text]

10.1200/jco.2022.40.16_suppl.4126

Cite

Citations (0)

RESEARCH AND APPLICATION OF GRAFTED SEEDLINGS HEALING ROOM

Acta Horticulturae (2015)

Dong Wang Zhiwei Zhou Yunlong Bu Jieqiang Zhuo L. Z. Chen

The healing of grafted seedlings is to complete the process of callus induction, differentiation and union of stock and scion. This stage is important to ensure the survival of grafted seedlings, especially for scion since the roots of scion will be removed in the vast majority grafting. The scion does not form the same type of organization with the rootstock. The two conducting tissues are not uniformly connected; thus, the scion and rootstock do not transport water and nutrients through the roots. To prevent this problem, suitable relative humidity and temperature must be provided to ensure the scion will not wilt and the healing process of grafted seedlings is properly completed. Beijing Jingpeng International Hi-Tech Corporation developed a healing room for grafted seedlings, which features an intelligent environment control system, cycle ventilation equipment, spray humidification system, CO2 fertilization equipment, lighting system, temperature control system, seedling frame, and perimeter protection. The healing room can provide a suitable artificial environment for newly grafted vegetable seedlings. The environment can be controlled based on the healing requirements of grafted seedlings through automatic control of artificial climate, including relative humidity, temperature, light, wind speed, and other environmental factors. Providing such an environment can promote callus growth, improve the survival rate of grafted seedlings, and increase the mass production of seedlings.

10.17660/actahortic.2015.1086.4

Cite

Citations (8)

Identification of Mobile Colistin Resistance Gene mcr-10 in Disinfectant and Antibiotic Resistant Escherichia coli from Disinfected Tableware

Antibiotics (2022)

Senlin Zhang Honghu Sun Guangjie Lao Zhiwei Zhou Zhuochong Liu

The widespread escalation of bacterial resistance threatens the safety of the food chain. To investigate the resistance characteristics of

Disinfectant

Colistin

Benzalkonium chloride

Cetylpyridinium chloride

10.3390/antibiotics11070883

Cite

Citations (6)

Cancer cells invasion to the gastric bare area adipose tissue: a poor prognostic predictor for gastric cancer

Research Square (Research Square) (2020)

Yongming Chen Shuhang Xu Chunyu Huang Yihong Ling Chengcai Liang

Abstract Background: The relationship between gastric bare area adipose tissues invasion (GBAI) confirmed pathologically and the prognosis of gastric cancer (GC) patients is undefined. Till present, there hasn’t been literature investigating this phenomenon. Here, we aimed at analyzing the implication of GBAI in GC. Methods: The data of 1822 patients who underwent radical surgery between January 2000 and December 2013 at the Sun Yat-sen University Cancer Center were retrieved. Pathologically, tumor deposits (TDs) located >5mm from the leading edge of the primary tumor and the lymph nodes (LNs) station number 1, 2, 7, and 9 were considered as GBAI. Kaplan-Meier method, log-rank test and Cox’s proportional hazards model were employed to analyze. Results: 205 (11.3%) patients were pathologically diagnosed with GBAI, which was more commonly found in proximal or linitis lastica than distal GC (P<0.001). There was significant difference in 5-year survival between patients with and without GBAI for stages IIB, IIIA, IIIB, IIIC, respectively (P<0.009 for IIB, IIIA and IIIB, P=0.021 for IIIC). Among the 205 GBAI patients, 61 had detailed radiological follow-up data in which 26 (34.7%) were found to have retroperitoneal infiltration, 27 (36.0%) had peritoneal metastasis, 10 (13.3%) had hematogenous metastasis, 16 (21.3%) had lymphatic metastasis, and 16 (21.3%) had others. Conclusions: GBAI was identified as a predictor of unfavourable prognosis for GC and was more commonly found in the proximal or linitis plastica of the stomach than in distal stomach. Retroperitoneal infiltration was one of the most commonly identified metastatic route for GC associated with GBAI after radical surgery.

Linitis plastica

Lymphovascular invasion

Distant metastasis

Infiltration (HVAC)

10.21203/rs.3.rs-52811/v2

Cite

Citations (0)

Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma

The International Journal of Biological Markers (2009)

Miao‐Zhen Qiu Junzhong Lin Zhi‐Qiang Wang Feng‐Hua Wang Zhizhong Pan

The aim of this longitudinal study was to try and improve the specificity of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 in monitoring tumor recurrence in patients with resectable gastric adenocarcinoma by setting suitable elevation levels.One hundred eighty-one patients with resectable gastric adenocarcinoma were considered. Serum samples were obtained preoperatively and every 3 months postoperatively.Preoperative CEA and CA19-9 positivity rates were 19.9% and 18.2%. The specificity and sensitivity of CEA elevation to monitor recurrence were 92.9% and 23.4% versus 76.5% and 78.9% in CEA-negative versus CEA-positive patients, respectively. For CA19-9 the specificity and sensitivity were 95.0% and 18.8% versus 60.0% and 83.3% in CA19-9-negative versus CA19-9-positive patients, respectively. When we set the elevation level of CEA at 5 ng/mL, the specificity of CEA elevation to monitor recurrence increased to 94.1% for CEA-positive patients. The specificity increased to 93.3% for CA19-9-positive patients when the CA19-9 elevation level was set at 100 U/mL.For CEA- or CA19-9-positive patients with resectable gastric adenocarcinoma we can increase the specificity of CEA and CA19-9 by setting the elevation level of CEA at 5 ng/mL and CA19-9 at 100 U/mL.

Carcinoembryonic antigen

CA19-9

10.1177/172460080902400407

Cite

Citations (13)

Erratum to: Elevated Controlling Nutritional Status (CONUT) Score is Associated with Poor Long-term Survival in Patients with Low-grade Soft-tissue Sarcomas Treated with Surgical Resection

Clinical Orthopaedics and Related Research (2021)

Yao Liang Tao Hou Yi Que Baiwei Zhao Wei Xiao

Four tables were not included in the published study, “Elevated Controlling Nutritional Status (CONUT) Score is Associated with Poor Long-term Survival in Patients with Low-grade Soft-tissue Sarcomas Treated with Surgical Resection”. Table 1, below, corresponded with data in Patients and Methods section under the subheads, Patients and Tumor Characteristics and Clinical Data Collection and the CONUT Score Table 1. - Baseline characteristics of all patients Variable Characteristics Number % Gender Men 393 60 Women 265 40 Age (years) < 50 437 66 ≥ 50 221 34 BMI (kg/m2) < 18.5 80 12 18.5 to 25.0 430 65 ≥ 25.0 148 23 Pathological types Fibrosarcoma 151 23 Liposarcoma 91 14 Undifferentiated pleomorphic sarcoma 149 23 Leiomyosarcoma 27 4 Synovial sarcoma 77 12 Rhabdomyosarcoma 38 6 Alveolar soft part sarcoma 12 2 Epithelioid sarcoma 15 2 Angiosarcoma 13 2 Malignant peripheral nerve sheath tumor 38 6 Mesenchymal chondrosarcoma 20 3 Others 27 4 Tumor size < 5 cm 322 49 ≥ 5 cm 336 51 Tumor site Upper extremity 82 13 Lower extremity 216 33 Thoracic/trunk/abdominal wall 191 29 Intra-abdominal 71 11 Head/neck 80 12 Others* 18 3 Tumor depth Superficial 235 36 Deep 423 64 Tumor grade G1 130 20 G2 304 46 G3 201 31 GX 23 4 AJCC stage IA 88 13 IB 45 7 II 233 35 IIIA 132 20 IIIB 75 11 IV 12 2 Unknown 73 11 NLR < 2.51 453 69 ≥ 2.51 205 31 PLR < 164.5 516 78 ≥ 164.5 142 22 HS-mGPS 0 311 62 1-2 194 38 CONUT 0 227 35 1 208 32 2-12 223 34 Albumin score 0 606 92 2/4/6 52 8 Total lymphocyte score 0 327 50 1 253 38 2/3 78 12 Total cholesterol score 0 477 73 1 118 18 2/3 63 10 Endpoint Alive 484 74 Dead 174 26 Recurrence Yes 250 38 No 408 62 Metastasis Yes 94 14 No 564 86 Adjuvant therapy None 467 71 Chemotherapy 41 6 Radiotherapy 44 7 Combined chemoradiotherapy 11 2 Unknown 95 14 *Including the perineum, crissum, pleural cavity, and pulmonary systemHS-mGPS = high-sensitivity modified Glasgow prognostic score Table 2, below, corresponded with data in the Results section under the subhead, Correlation Between the CONUT Score and Clinicopathologic Characteristics. Table 2. - Relationships between the CONUT score and patient characteristics Characteristics CONUT score p value OR (95% CI) Low (n = 435), (%) High (n = 223), (%) Gender 0.761 Men 177 (41) 88 (40) Women 258 (59) 135 (60) 1.05 (0.76-1.46) Age at operation (years) 0.848 < 50 290 (67) 147 (66) ≥ 50 145 (33) 76 (34) 1.03 (0.74-1.45) Tumor diameter (cm) 0.020 < 5 cm 227 (52) 95 (43) ≥ 5 cm 208 (48) 128 (57) 1.47 (1.06-2.04) Tumor depth 0.004 Superficial 172 (40) 63 (28) Deep 263 (60) 160 (72) 1.66 (1.17-2.36) Tumor grade 0.001 G1 99 (23) 31 (14) G2 209 (48) 95 (43) 1.45 (0.91-2.32) G3 112 (26) 89 (40) 2.54 (1.56-4.14) Missing data 15 (3) 8 (3) 1.70 (0.66-4.40) AJCC stage < 0.001 IA + IB 102 (23) 31 (14) II 161 (37) 72 (33) 1.47 (0.90-2.40) II + IV 140 (33) 79 (35) 1.86 (1.14-3.02) Unknown 32 (7) 41 (18) 4.22 (2.29-7.78) NLR < 0.001 < 2.51 354 (81) 99 (44) ≥ 2.51 81 (19) 124 (56) 5.48 (3.83-7.83) PLR < 0.001 < 164.5 390 (90) 126 (57) ≥ 164.5 45 (10) 97 (43) 6.67 (4.44-10.02) Endpoint < 0.001 Alive 352 (81) 132 (59) Dead 83 (19) 91 (41) 2.92 (2.04-4.18) Recurrence < 0.001 No 294 (68) 114 (51) Yes 141 (32) 109 (49) 1.99 (1.43-2.78) Metastasis < 0.001 No 391 (90) 173 (78) Yes 44 (10) 50 (22) 2.57 (1.65-4.00) Tables 3 and 4, both below, corresponded with data in the Results section under the subhead, Survival Analysis. Table 3. - Multivariate analyses of risk factors associated with OS in patients with STS Variable HR (95% CI) p value Tumor depth 0.017 Superficial 1 (reference) Deep 1.71 (1.10-2.65) Tumor grade < 0.001 G1 1 (reference) G2 3.19 (0.46-22.06) G3 8.97 (1.28-62.73) AJCC stage 0.009 IA + IB 1 (reference) II 0.38 (0.06-2.47) III + IV 0.69 (0.11-4.34) CONUT score < 0.001 Low 1 (reference) High 1.86 (1.32-2.61) Table 4. - Multivariate analyses of risk factors associated with DFS in patients with STS Variable HR (95% CI) p value Tumor depth < 0.001 Superficial 1 (reference) Deep 2.03 (1.50-2.73) Tumor grade < 0.001 G1 1 (reference) G2 1.94 (1.28-2.96) 0.002 G3 2.71 (1.75-4.20) < 0.001 CONUT score < 0.001 Low 1 (reference) High 1.63 (1.26-2.11) CORR apologizes for the error.

Synovial Sarcoma

Undifferentiated Pleomorphic Sarcoma

10.1097/corr.0000000000002019

Cite

Citations (0)

Cancer cells invasion to the gastric bare area adipose tissue: a poor prognostic predictor for gastric cancer

Research Square (Research Square) (2020)

Yongming Chen Shuhang Xu Chunyu Huang Yihong Ling Chengcai Liang

Abstract Background: The relationship between gastric bare area adipose tissues invasion (GBAI) confirmed pathologically and the prognosis of gastric cancer (GC) patients is undefined. Till present, there hasn’t been literature investigating this phenomenon. Here, we aimed at analyzing the implication of GBAI in GC. Methods: The data of 1822 patients who underwent radical surgery between January 2000 and December 2013 at the Sun Yat-sen University Cancer Center were retrieved. Pathologically, tumor deposits (TDs) located >5mm from the leading edge of the primary tumor and the lymph nodes (LNs) station number 1, 2, 7, and 9 were considered as GBAI. Kaplan-Meier method, log-rank test and Cox’s proportional hazards model were employed to analyze. Results : 205 (11.3%) patients were pathologically diagnosed with GBAI, which was more commonly found in proximal or linitis lastica than distal GC ( P <0.001). There was significant difference in 5-year survival between patients with and without GBAI for stages IIB, IIIA, IIIB, IIIC, respectively ( P <0.009 for IIB, IIIA and IIIB, P =0.021 for IIIC). Among the 205 GBAI patients, 61 had detailed radiological follow-up data in which 26 (34.7%) were found to have retroperitoneal infiltration, 27 (36.0%) had peritoneal metastasis, 10 (13.3%) had hematogenous metastasis, 16 (21.3%) had lymphatic metastasis, and 16 (21.3%) had others. Conclusions: GBAI was identified as a predictor of unfavourable prognosis for GC and was more commonly found in the proximal or linitis plastica of the stomach than in distal stomach. Retroperitoneal infiltration was one of the most commonly identified metastatic route for GC associated with GBAI after radical surgery.

Linitis plastica

Lymphovascular invasion

Infiltration (HVAC)

Distant metastasis

10.21203/rs.3.rs-52811/v1

Cite

Citations (1)

Future focus: unlocking self-control and meaning in life to combat smartphone addiction

Current Psychology (2024)

Xiaolong Li Zhiwei Zhou Qinqhuan He Ting Su Chengli Huang

Abstract Existing literature shows a link between future temporal focus (FTF) and smartphone addiction (SA). However, the precise psychological mechanisms underlying this relationship remain inadequately explored, despite the recognized importance of meaning in life (MIL) and self-control (SC) in influencing the FTF-SA correlation. This study seeks to elucidate the mediating roles of MIL and SC within the FTF-SA relationship. A total of 462 university students ( M age = 19.57, SD age = 1.09) participated in the study, completing scales for FTF, MIL, SC, and SA, which were analyzed using Structural Equation Modeling (SEM). Our findings indicate that MIL and SC serve as mediators in the FTF-SA relationship. Specifically, FTF diminishes tendencies towards SA through the serial mediation effect of MIL and SC. These results suggest that incorporating future-oriented perspectives and focusing on the cultivation of MIL and SC are critical components in interventions targeting SA. Moreover, this study offers guidelines for future research aimed at developing addiction therapies and preventive strategies related to MIL and SC.

Smartphone addiction

10.1007/s12144-024-06842-4

Cite

Citations (0)

LAG3-PD1 or CTLA4-PD1 inhibition in advanced melanoma: Indirect cross comparisons of the CheckMate-067 and relativity-047 trials.

Journal of Clinical Oncology (2022)

Run‐Cong Nie Yun Wang Shuqiang Yuan Yingbo Chen Zhiwei Zhou

e21511 Background: There remain unmet needs to identify novel immune checkpoint inhibitors to improve the benefit-risk profile of immunotherapy for advanced melanoma. The comparison between LAG3-PD1 inhibition and CTLA4-PD1 inhibition was lacked. To compare the inhibition of lymphocyte-activation gene 3 (LAG3) plus programmed cell death 1 (PD-1) versus the inhibition of cytotoxic T-lymphocyte antigen 4 (CTLA-4) plus PD-1 in patients with previously untreated advanced melanoma. Methods: The individual participant data (IPD) data were extracted from the KM plots using a graphical reconstructive algorithm through eligible. Log-rank, Cox proportional hazard model, Bayesian hierarchical model with time-varying hazard ratio (HR) effect, and restricted mean survival time (RMST) were performed to estimate survival benefits. The primary endpoint was progression-free survival. Results: The CheckMate-067 (N = 630) and RELATIVITY-047 (N = 714) trials were included for analysis. The graphical reconstructive algorithm showed that IPD had similar HRs and log-rank values as the original plots. The HR of nivolumab-relatlimab (LAG3 inhibitor) versus nivolumab-ipilimumab (CTLA4 inhibitor) was 1.19 (95% confidence interval [CI] 0.96 to1.48). The 24-months RMST of nivolumab-relatlimab versus nivolumab alone was 2.35 (95% CI 0.77 to 3.94) months, compared with 1.87 (95% CI 0.25-3.49) months for nivolumab-ipilimumab versus nivolumab. The Bayesian hierarchical model showed that patients treated with nivolumab-relatlimab had earlier PFS benefits than those with nivolumab-ipilimumab. Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients using nivolumab-relatlimab and 55.0% of patients using nivolumab-ipilimumab. Conclusions: These findings suggest that the PFS of LAG3-PD1 and CTLA4-PD1 inhibition were similar and that LAG3-PD1 inhibition tended to exhibit earlier survival benefit and lesser TRAEs.

10.1200/jco.2022.40.16_suppl.e21511

Cite

Citations (0)

Design and application of MAP bags for cherry tomato

Zhongguo shucai (2004)

M.L. Wang Zhiwei Zhou

Cherry tomato

Source

Cite

Citations (0)